

Dartmouth College

Dartmouth Digital Commons

Dartmouth Scholarship

Faculty Work

1-2013

Alginate Lyase Exhibits Catalysis-Independent Biofilm Dispersion and Antibiotic Synergy

John W. Lamppa
Dartmouth College

Karl E. Griswold
Dartmouth College

Follow this and additional works at: <https://digitalcommons.dartmouth.edu/facoa>



Part of the [Biochemistry, Biophysics, and Structural Biology Commons](#)

Dartmouth Digital Commons Citation

Lamppa, John W. and Griswold, Karl E., "Alginate Lyase Exhibits Catalysis-Independent Biofilm Dispersion and Antibiotic Synergy" (2013). *Dartmouth Scholarship*. 2527.
<https://digitalcommons.dartmouth.edu/facoa/2527>

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Alginate Lyase Exhibits Catalysis-Independent Biofilm Dispersion and Antibiotic Synergy

John W. Lamppa,^{a,*} Karl E. Griswold^{a,b}

Thayer School of Engineering^a and Molecular and Cellular Biology Program,^b Dartmouth, Hanover, New Hampshire, USA

More than 2 decades of study support the hypothesis that alginate lyases are promising therapeutic candidates for treating mucoid *Pseudomonas aeruginosa* infections. In particular, the enzymes' ability to degrade alginate, a key component of mucoid biofilm matrix, has been the presumed mechanism by which they disrupt biofilms and enhance antibiotic efficacy. The systematic studies reported here show that, in an *in vitro* model, alginate lyase dispersion of *P. aeruginosa* biofilms and enzyme synergy with tobramycin are completely decoupled from catalytic activity. In fact, equivalent antibiofilm effects can be achieved with bovine serum albumin or simple amino acids. These results provide new insights into potential mechanisms of alginate lyase therapeutic activity, and they should motivate a careful reexamination of the fundamental assumptions underlying interest in enzymatic biofilm dispersion.

Premature mortality among cystic fibrosis (CF) patients is typically associated with chronic airway infection by the opportunistic pathogen *Pseudomonas aeruginosa* (1). Upon colonization of the airway, *P. aeruginosa* causes a range of clinical complications, including stimulation of a hyperinflammatory response, obstruction of the pulmonary tract, and progressive loss of lung function (1–3). The bacterium's persistence within the CF lung is thought to result in large part from a biofilm mode of growth (2, 4), which can subvert both the host immune response and antibacterial therapies (5). In contrast to environmental niches, in the CF lung, *P. aeruginosa* generally transitions to a mucoid phenotype characterized by overproduction of the exopolysaccharide alginate (6). This copolymer of (1,4)-linked β -D-mannuronic acid and α -L-guluronic acid alters biofilm architecture and function (7) and thereby compounds *P. aeruginosa*'s persistence in the chronically inflamed airway (5). Indeed, alginate is one of the most extensively studied *P. aeruginosa* virulence factors (8).

Given alginate's contribution to mucoid biofilm structure, its function in bacterial virulence, and its role in the persistent nature of lung infections, it has long been considered an attractive target for interventional therapies (6). In particular, biocatalytic degradation of mucoid *P. aeruginosa* biofilms using alginate lyase enzymes (EC 4.2.2.3) has been the subject of more than 20 years of research. Alginate lyase treatment has been shown to reduce viscosity in cultures of clinical isolates and in CF sputum (9, 10); it strips biofilms from abiotic surfaces (11, 12), it enhances phagocytosis and killing of *P. aeruginosa* by human immune cells (13–15), and it improves the efficacy of various antipseudomonal antibiotics (14, 16–19). In aggregate, these reports make a rather convincing case for the use of inhaled alginate lyases for treating chronic *P. aeruginosa* infections of the CF lung, although no clinical trials have been conducted to date.

In an effort to further bolster the rationale for therapeutic alginate lyases, we set out to conduct systematic studies analyzing the solution phase kinetics, biofilm-disrupting potential, and antibiotic synergy of two promising enzyme candidates. *Sphingomonas* sp. A1 alginate lyase (A1-III) has been shown previously to exhibit high levels of activity toward bacterial alginate (20) and has also been subjected to molecular engineering with an eye toward ther-

apeutic applications (12, 21). *P. aeruginosa* alginate lyase (AlgL) is produced by the CF-associated pathogen itself, and its confirmed role in bacterial alginate biosynthesis (22, 23) suggests the enzyme is an obvious choice for developing alginate-degrading CF biotherapies. On a superficial level, our results are entirely consistent with the encouraging outcomes of prior alginate lyase studies. Our systematic approach, however, has for the first time revealed that enzyme-mediated biofilm disruption and antibiotic synergy are decoupled from catalytic activity. The results described here suggest the need to carefully reexamine the veracity of fundamental assumptions motivating interest in therapeutic alginate lyases.

MATERIALS AND METHODS

Bacterial strains. The mucoid *P. aeruginosa* clinical isolate FRD1 and its nonmucoid derivative, SMC406, were obtained from the G. O'Toole laboratory (Geisel School of Medicine at Dartmouth, Hanover, NH). SMC406 varies from FRD1 only in the deletion of the *algT* gene, which effectively eliminates alginate biosynthesis (24). The *Escherichia coli* expression strain SHuffle T7 Express {*fhuA2 lacZ::T7 gene1 [lon] ompT ahpC gal kcat::pNEB3-r1-cDsbC (Spec^r lacI^q) Δ trxB sulA11 R(mcr-73::miniTn10-Tet^r)2 [dcm] R(zgb-210::Tn10 -Tet^r) endA1 Δ gor Δ (mcrC-mrr)114::IS10}* was purchased from New England BioLabs (Ipswich, MA).

Cloning of the A1-III and AlgL alginate lyases. The alginate lyase gene *algL* was amplified from the *P. aeruginosa* PAO1 genome using a 5' primer with an ATG start codon, homology to base pairs 82 to 96 on the native gene, and a 3' primer with either a TGA stop codon or a C-terminal hexahistidine tag followed by a TGA stop codon. The amplified AlgL genes were ligated into the pET28b expression vector and transformed into electrocompetent SHuffle T7 Express. Individual clones were sequence verified. Additionally, pET28b constructs containing either *Sphingomonas* sp. alginate lyase A1-III or a C-terminal hexahistidine-tagged variant

Received 28 August 2012 Returned for modification 25 September 2012

Accepted 11 October 2012

Published ahead of print 15 October 2012

Address correspondence to Karl E. Griswold, karl.e.griswold@dartmouth.edu.

* Present address: John Lamppa, 300 Technology Square, Cambridge, Massachusetts, USA.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.01789-12

(A1-III-His) (12) were transformed into SHuffle T7 Express, and individual clones were sequence verified.

The catalytically inactivated double point mutant of A1-III-His (A1-DM-His) was constructed by targeting two of the active-site residues involved in the enzyme's β -elimination mechanism (25). Mutation H188A consisted of switching the histidine 188 GTG codon to a CGC codon, while mutation Y242F replaced the tyrosine 242 GTA codon with a GAA codon. The mutated gene was then ligated into the pET28b expression vector and transformed into SHuffle T7 Express, and individual clones were sequence verified.

Expression and purification of alginate lyases. Expression hosts were grown overnight in 8 ml of LB supplemented with 30 μ g/ml kanamycin (LB-KAN30) at 30°C. The overnight cultures were then subcultured 1:100 into 500 ml of fresh LB-KAN30 and grown to mid-log phase at 30°C, after which the cells were equilibrated at 25°C for 30 min and then induced with 0.5 mM IPTG (isopropyl- β -D-thiogalactopyranoside) for 21 h. Following induction, the cell cultures were centrifuged at $6,000 \times g$ at 4°C for 10 min, and the total cell pellet for each construct was resuspended in 5 ml of buffer A (20 mM NaH_2PO_4 , pH 6.5). The resuspended pellets were transferred to 10-ml Pyrex beakers, equilibrated on ice for 20 min, and disrupted by sonication with 24 cycles of 10 s on and 10 s off (Fisher 550 Sonic Dismembrator). Whole-cell lysate was centrifuged at $17,000 \times g$ at 4°C for 20 min, and the soluble fraction was filtered through a 0.22- μ m polyethersulfone (PES) membrane.

Filtered soluble cell extract containing AlgL was loaded onto a 30-ml hydroxyapatite column (Calbiochem, La Jolla, CA) equilibrated with buffer A. Buffer A continued to run for 10 ml at 2 ml/min before changing to a step gradient of 30% buffer A and 70% buffer B (500 mM NaH_2PO_4 , pH 6.5) for 60 ml, followed by 100% buffer B for an additional 65 ml. At 100% buffer B, a single peak, containing AlgL and other proteins, was eluted. This peak was dialyzed against 50 mM KH_2PO_4 , 150 mM NaCl, pH 7, at 4°C and concentrated using a 10,000-molecular-weight cutoff (MWCO) centrifugal filter. Concentrated sample (300 μ l) was then loaded onto a 120-ml Superdex75 size exclusion chromatography (SEC) (GE Healthcare Life Sciences, Piscataway, NJ) column equilibrated with 50 mM KH_2PO_4 , 150 mM NaCl, pH 7. Flow was maintained at 0.6 ml/min, and purified AlgL was eluted as a single peak at 60 ml. Samples from the SEC were concentrated using a 3,000-MWCO centrifugal filter and stored at 4°C. Enzyme purity was assessed by SDS-PAGE, and the final protein concentrations were measured by A_{280} (NanoDrop 1000; Thermo Scientific, Waltham, MA) using a molar absorptivity of $67,050 \text{ cm}^{-1} \text{ M}^{-1}$, estimated with the VectorNTI software package (Invitrogen, Carlsbad, CA).

The same hydroxyapatite column and buffers were used to purify A1-III enzyme from corresponding soluble cell extract. The column was washed with buffer A for 20 ml at 2 ml/min, then increased to 5% B for 30 ml, increased again to 12% B for 50 ml, and finally 100% B for another 80 ml. An unresolved peak at 100 ml containing A1-III was collected and dialyzed against 50 mM KH_2PO_4 , 150 mM NaCl, pH 7 at 4°C before being concentrated with a 10,000-MWCO centrifugal filter. Two hundred microliters of the concentrated sample was then loaded onto the same Superdex75 SEC column, and purified A1-III was eluted at 60 ml under the same conditions described above. Samples did not require further concentration after SEC and were stored at 4°C. Enzyme purity was assessed by SDS-PAGE, and the protein concentration was measured by A_{280} (molar absorptivity = $63,350 \text{ cm}^{-1} \text{ M}^{-1}$).

In addition to the above-mentioned purification protocol, single-step immobilized metal ion affinity chromatography (IMAC) purification was also used as an alternative method for isolating the His-tagged variants. Briefly, 4 to 5 ml of filtered soluble cell extract was gently mixed with a 0.4-ml bed volume of nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qia-gen, Valencia, CA), which had been equilibrated with native lysis buffer (50 mM NaH_2PO_4 , 300 mM NaCl, and 10 mM imidazole, pH 8.0). Binding occurred at 4°C for 1 h, with gentle rocking, after which the column was drained and washed with 10 bed volumes of wash buffer (50 mM NaH_2PO_4 , 300 mM NaCl, and 20 mM imidazole, pH 8.0). Purified A1-III

was eluted in a native elution buffer (50 mM NaH_2PO_4 , 300 mM NaCl, 250 mM imidazole, pH 8.0), dialyzed into storage buffer (20 mM NaH_2PO_4 , pH 6.5), and kept at 4°C. Once again, enzyme purity was assessed by SDS-PAGE, and concentrations were determined by A_{280} .

Enzyme kinetic analysis with soluble substrates. Enzyme-mediated cleavage of the alginate carbohydrate backbone through beta elimination results in formation of a C-4–C-5 carbon-carbon π bond at the new nonreducing termini, causing a strong absorbance peak at 235 nm. Replicate kinetic analysis was conducted by monitoring product formation at 235 nm in UV-transparent 96-well plates (Costar Fisher number 3635). Using a multichannel pipette, 190- μ l aliquots of medium-viscosity brown seaweed alginate (BSWA) (Sigma number A2033) were mixed thoroughly with 10 μ l of enzyme residing in each well of the plate's upper row. BSWA dilutions were prepared in a reaction buffer (150 mM NaCl, 50 mM NaH_2PO_4 , pH 7.0) and ranged from 0.01% to 0.1% (wt/vol). Upon completion of mixing, the plate was transferred to a UV-visible plate reader (SpectraMax 190; Molecular Devices, Sunnyvale, CA), and the formation of product was tracked every 15 s over the course of 10 min. Initial slopes from absorbance-versus-time plots were determined for each substrate concentration, and nonlinear regression of the initial reaction rates versus substrate concentration was used to determine apparent V_{max} and K_m values for each enzyme. Kinetics with bacterial alginate substrate, purified from *P. aeruginosa* FRD1 as described previously (26), followed the same procedure (bacterial alginate follows the same cleavage mechanism as BSWA).

Biofilm cell viability assays. *P. aeruginosa* strains FRD1 and SMC406 were grown on LB agar plates at 37°C. Single colonies were selected and used to inoculate 3-ml cultures of tryptic soy broth (TSB). The cultures were placed on an orbital shaker for 21 h at 37°C before being diluted 1:1,000 in fresh TSB. Upon dilution, the cultures were aliquoted into 96-well minimum biofilm eradication concentration (MBEC) plates (Innovotech, Edmonton, AB, Canada) at a volume of 75 μ l per well. The corresponding peg lid was then placed on top of the plate, and the sides of the plate were sealed with strips of Breathe-Easy membrane (Diversified Biotech, Dedham, MA), which eliminated evaporation but still allowed gas permeability. The plates were incubated statically at 37°C for 20 h before the peg lids were removed, rinsed in sterile deionized water for 10 s, and placed into black, clear-bottom, 96-well treatment plates (Corning, Lowell, MA). The treatment plates contained 125 μ l of activity buffer (50 mM potassium phosphate, 150 mM NaCl, pH 7) only (untreated) or with one of the following agents: 100 or 500 μ g/ml tobramycin (MP Biomedicals, Solon, OH), 1,000 μ g/ml protein (A1-III-His, A1-DM-His, A53C-His-PEG [polyethylene glycol], AlgL-His, or bovine serum albumin [BSA]), the constituent amino acids of A1-III-His at the same molar concentrations contained in 1,000 μ g/ml of intact enzyme, the arginine constituent of A1-III-His at the same molar concentration contained in 1,000 μ g/ml of the intact enzyme, or arginine at the same molar concentration as the sum total of all amino acids in 1,000 μ g/ml A1-III-His. Additionally, 100 or 500 μ g/ml of tobramycin was combined with each of the protein and amino acid treatments to assess synergistic effects. The treatment plates were sealed with strips of Breathe-Easy membrane and statically incubated at 37°C for 12 h.

After treatment, the peg lids were removed from the treatment plates, rinsed in sterile deionized water for 10 s, and placed into black, clear-bottom, 96-well plates containing 125 μ l per well of alamarBlue (Invitrogen, Carlsbad, CA) to measure biofilm cell viability. Concurrently, alamarBlue was added to the treatment plates to measure the viability of any detached cells. All alamarBlue plates were sealed with Breathe-Easy membranes and statically incubated for 12 h at 37°C. Membranes and peg lids were then removed, and reduction of the alamarBlue resazurin compound was measured by fluorescence at an excitation wavelength of 540 nm (550-nm cutoff) and an emission wavelength of 585 nm. Additionally, alamarBlue background signal was measured in the presence of all treatments without cells and subtracted from the cell viability signal.




FIG 1 SDS-PAGE analysis of alginate lyase expression and purification. (A) *P. aeruginosa* AlgL. Lane 1, Bio-Rad Precision Plus Dual Color Standard; lane 2, AlgL soluble cell-free extract; lane 3, AlgL-His soluble cell-free extract; lane 4, AlgL eluted from hydroxyapatite; lane 5, AlgL-His eluted from hydroxyapatite; lane 6, AlgL following size exclusion chromatography; lane 7, AlgL-His following size exclusion chromatography. (B) *Sphingomonas* sp. A1-III. Samples containing the native and His-tagged proteins were loaded as for panel A.

SEM. Polystyrene peg lids were prefixed in 0.1 M PIPES [piperazine-*N,N'*-bis(2-ethanesulfonic acid)], pH 7, containing 50 mM L-lysine, 0.075% ruthenium red, and 2.5% glutaraldehyde for 30 min at room temperature. The peg lids were then fixed in 0.1 M PIPES, pH 7, containing 0.075% ruthenium red and 2.5% glutaraldehyde for 3 h at room temperature before being rinsed with 0.1 M PIPES, pH 7, for 20 min (the rinse was repeated three times). Dehydration of the peg lids was performed in 30%, 50%, 70%, and 95% ethanol for 5 min each, with 2 final changes in 100% ethanol for 5 min each. The peg lids were then air dried in a desiccator for 72 h. Upon completion of air drying, individual pegs were snapped off from the lids with tweezers and mounted on scanning electron microscopy (SEM) stubs with a layer of melted apiezon wax. The mounted pegs were then sputter coated with gold and palladium and viewed by SEM (XL30 ESEM FEG; FEI, Hillsboro, OR).

Statistical analysis. Statistical significance was assessed using one-way analysis of variance (ANOVA) and *post hoc* Tukey's multiple-comparison tests. Significance was determined at an α value of 0.05.

RESULTS

Selection, cloning, and production of alginate lyases. We selected two enzyme candidates for comparative analysis. *Sphingomonas* sp. A1-III has been reported to exhibit particularly high levels of activity toward bacterial alginate (20) and has been the subject of extensive study and preclinical development (9, 12, 21). *P. aeruginosa* AlgL has naturally evolved to degrade bacterial alginate, and the enzyme was shown previously to facilitate detachment of *P. aeruginosa* from biofilms (27). The *algL* gene was amplified from *P. aeruginosa* PAO1 genomic DNA, cloned into the pET28b expression vector, and transformed into electrocompetent *E. coli* SHuffle T7 Express. A gene encoding a variant of AlgL bearing a C-terminal hexahistidine tag (AlgL-His) was constructed in a similar manner. Shake flask cultures of the two expression strains were induced overnight, and the proteins were purified from whole-cell lysates via hydroxyapatite and then SEC. The yields were 0.39 mg/liter for native AlgL and 2.3 mg/liter for AlgL-His, with both proteins exhibiting >90% purity (Fig. 1A). The synthesis and cloning of genes encoding the native A1-III enzyme and its C-terminal His-tagged variant have been described previously (12). Expression and purification of A1-III and A1-III-His followed the same procedures described for AlgL above. The final yields for the two proteins were 9.3 mg per liter of bacterial culture and 15 mg per liter of culture, respectively, and again, both proteins were >90% pure following SEC (Fig. 1B).

In addition to the two-step hydroxyapatite and SEC purification described above, the His-tagged variants AlgL-His and A1-

III-His were purified by one-step IMAC nickel chromatography. IMAC purification resulted in 7.6 mg AlgL-His per liter of bacterial culture and 13 mg A1-III-His per liter of culture. The purity of the proteins eluted from the IMAC resin was comparable to that obtained with the two-step purification (data not shown). It bears noting that the IMAC yields for AlgL-His were at least 3-fold greater than any previously reported purification of the enzyme from shake flask cultures (28, 29). Importantly, kinetic analysis (described below) showed that the IMAC-purified proteins were indistinguishable from samples prepared by two-step chromatography.

Solution phase enzyme kinetics. Intuition suggests that the therapeutic potential of alginate lyase enzymes should be directly proportional to their catalytic firepower, and therefore, the solution phase kinetics of alginate degradation were used to compare the prospective utilities of the various enzymes (Table 1). Initial studies were conducted with commercially available BSWA, a standard substrate for analysis of alginate lyase activity. In comparing the two native enzyme constructs, A1-III exhibited a 10-fold greater V_{\max} than AlgL, but the difference in K_m values was not statistically significant. With the BSWA substrate, the V_{\max} and K_m values for the native A1-III enzyme were similar to those of the His-tagged analog A1-III-His, as were the respective values for AlgL and AlgL-His. Thus, appending a C-terminal hexahistidine tag onto either of the two alginate lyases did not substantially alter their solution phase kinetics.

BSWA is a readily available commodity product commonly used for characterizing alginate lyase activity, but the ultimate therapeutic target is alginate produced by the bacterium *P. aerugi-*

TABLE 1 Pseudo Michaelis-Menten kinetic parameters with BSWA and bacterial (FRD1) alginate substrates

Enzyme	Substrate	V_{\max} [$\Delta A_{235} \text{ (min} \cdot \text{mg)}^{-1}$]	K_m ($\mu\text{g/ml}$)	V_{\max}/K_m
AlgL	BSWA	26 ± 1	70 ± 10	0.36 ± 0.05
AlgL-His	BSWA	35 ± 2	40 ± 10	0.8 ± 0.2
	FRD1	127 ± 6	840 ± 70	0.15 ± 0.01
A1-III	BSWA	290 ± 20	39 ± 9	8 ± 2
A1-III-His	BSWA	337 ± 9	100 ± 10	3.4 ± 0.4
	FRD1	310 ± 10	420 ± 40	0.74 ± 0.08




FIG 2 Analysis of cell viability in *P. aeruginosa* biofilms following alginate lyase treatments. (A) Mucoid FRD1 biofilms were treated for 12 h with either 500 µg/ml tobramycin (Tob), 1,000 µg/ml alginate lyase, or a combination thereof. Subsequently, cell viability was quantified with alamarBlue, and the results were normalized to untreated biofilms. (B) Nonmucoid SMC406 biofilms were treated in the same manner as for panel A, except that tobramycin concentrations were lowered to 100 µg/ml. The error bars represent standard deviations from four replicates. Statistically significant ($\alpha = 0.05$) differences relative to untreated biofilms are marked with asterisks.

nosa. Bacterial alginate differs from BSWA in its relative mannuronic and guluronic acid content, as well as the presence of acetyl esters on C-2 and C-3 hydroxyl groups (30). To compare the activities of the two enzymes on a more clinically relevant substrate, the kinetics of A1-III-His and AlgL-His were determined with alginate purified from *P. aeruginosa* strain FRD1, a mucoid clinical isolate (Table 1). The V_{\max} value for A1-III-His was essentially unchanged compared to its value with the BSWA substrate, but the enzyme's K_m for bacterial alginate was at least 4-fold higher. Thus, A1-III-His exhibited strong activity toward both BSWA and bacterial alginate, but it required substantially higher concentrations of the latter to achieve maximum rates of degradation. The AlgL-His enzyme, on the other hand, was found to have a significant increase in both K_m (20-fold) and V_{\max} (3.6-fold) when comparing the bacterial substrate to BSWA. The *P. aeruginosa* enzyme, therefore, achieves higher maximum rates of degradation with its native bacterial substrate, but analogous to A1-III-His, it requires concentrated substrate solutions to do so. Despite the increased activity of AlgL-His toward its native substrate, the A1-III-His enzyme maintained a significant advantage with respect to the maximum degradation rates of bacterial alginate (>2-fold). In contrast, the catalytic efficiencies (V_{\max}/K_m) of the two enzymes were not significantly different for the therapeutically relevant substrate.

Treatment of mucoid and nonmucoid biofilms with A1-III-His and tobramycin. Within the hydrogel environment of bacterial biofilms, one may reasonably assume that the local concentrations of alginate will be quite high. Under conditions of high substrate concentration, V_{\max} , as opposed to V_{\max}/K_m , is the most relevant kinetic parameter. We therefore elected to examine only A1-III-His in the initial biofilm assays. While we had previously validated the biofilm-disrupting potential of A1-III-His using lectins to quantify alginate in enzyme-linked immunosorbent assay (ELISA)-type assays (12), here, we sought to quantify bactericidal activity within established biofilms. The alamarBlue reagent had been validated previously as an accurate reporter of *P. aeruginosa* viability in both planktonic cultures and biofilms (31). Thus, alamarBlue was used to monitor relative viability in the subsequent studies.

Treatment of mucoid FRD1 biofilms with 500 µg/ml of tobramycin, a clinically relevant concentration (32), resulted in a 48% reduction in cell viability compared to untreated controls (Fig. 2A). Standalone treatment with 1,000 µg/ml of A1-III-His showed a 40% reduction in alamarBlue signal, which likely resulted from enzyme-mediated cellular detachment as opposed to direct bactericidal action. In contrast, the combination of the two treatments (500 µg/ml tobramycin with 1,000 µg/ml of A1-III-His) repeatedly resulted in complete elimination of viable cell signal. Given the exceptional efficacy of the combined treatment on FRD1 biofilms, a simple control study was designed to confirm that the synergistic effect was a function of alginate degradation. Specifically, the treatment study with tobramycin and A1-III-His was repeated using the isogenic, nonmucoid *P. aeruginosa* strain SMC406 (Fig. 2B). The tobramycin treatment, lowered to 100 µg/ml to account for the greater sensitivity of nonmucoid strains (7), failed to reduce viable cells in the biofilm to a statistically significant degree. Surprisingly, the standalone A1-III-His treatment reduced alamarBlue signal by 40%, the same as observed with FRD1. Also similar to the results with FRD1, the combination treatment reduced SMC406 cell viability to background levels. These results were unanticipated, as the SMC406 strain does not produce alginate and should therefore be unaffected by alginate lyase treatment.

Given the unexpected results with the nonmucoid SMC406 strain, studies were designed to more rigorously assess the role of alginate degradation in FRD1 biofilm disruption. Based upon an X-ray crystal structure and a hypothesized mechanism (25), an active-site double mutant (H188A and Y242F) of A1-III-His was constructed (here, the double mutant is referred to as A1-DM-His). The A1-DM-His protein was expressed and purified at levels comparable to A1-III-His, but the purified double mutant exhibited no detectable activity on BSWA, even at enzyme concentrations 40-fold higher than those used to characterize the active biocatalyst (data not shown). The inactive A1-DM-His enzyme was used to treat both mucoid FRD1 and nonmucoid SMC406 biofilms alone and in combination with tobramycin (Fig. 2). As a single-agent treatment, A1-DM-His reduced biofilm signals by 25%, whereas in combination with tobramycin, it reduced biofilm




FIG 3 Analysis of *P. aeruginosa* viability following biofilm treatments. Mucoic FRD1 biofilms were treated for 12 h with a panel of biologic reagents, tobramycin, or combinations thereof. alamarBlue was then used to quantify cell viability in the remaining adherent biofilm (black bars), as well as in the treatment supernatant containing detached planktonic cells (white bars). (A) A1-DM-His alginate lyase and BSA were used to assess the effects of protein treatments that lacked alginate-degrading activity. (B) Treatments consisting of individual amino acids were used to assess whether higher-order protein structure was required for tobramycin synergy. The treatments were composed of (i) A1-III-His AA, with each individual amino acid at the same concentration as its specific molar contribution to 1,000 $\mu\text{g/ml}$ intact A1-III-His; (ii) A1-III-His Arg, with arginine at the same concentration as its specific molar contribution to 1,000 $\mu\text{g/ml}$ intact A1-III-His; and (iii) arginine, with arginine at the same molar concentration as the total of all individual amino acids in 1,000 $\mu\text{g/ml}$ intact A1-III-His. (C) Treatment with diverse alginate lyase enzymes was used to assess the effects of varied catalytic activity and proteolytic sensitivity. A1-III-His was repeated as a positive control. AlgL-His was included as a reduced-activity enzyme evolved to function specifically on bacterial alginate. A53C-His-PEG is a genetically engineered and PEGylated variant of A1-III-His that exhibits nearly identical solution phase kinetics but should have greater resistance to proteolytic degradation. The error bars represent standard deviations from six replicates. For biofilm cells, statistically significant ($\alpha = 0.05$) differences relative to untreated biofilm are marked with asterisks. For planktonic cells, statistically significant ($\alpha = 0.05$) differences relative to untreated biofilm are marked with pound signs.

cell signals to background levels. The latter result was indistinguishable from those achieved with the wild-type enzyme and tobramycin combination. Thus, it was concluded that A1-III-His antibacterial synergy with tobramycin was decoupled from catalytic activity.

Treatment of mucoic biofilms with proteins lacking alginate-degrading activity. While the above-mentioned results demonstrated that catalytic activity was irrelevant to biofilm dispersion and tobramycin synergy, they did not rule out the possibility that the observed antibiofilm effects resulted from some other molecular feature specific to the A1-III alginate lyase protein. To test this hypothesis, the FRD1 biofilm studies were repeated with the inactive A1-DM-His enzyme, as well as BSA as a sham treatment (Fig. 3A). In addition to analyzing cell viability within the treated biofilms, viable cells were also quantified in the treatment supernatant itself. Thus, the new studies captured the treatment effects on both adherent and detached cell populations. BSA treatment affected neither biofilm nor planktonic alamarBlue signal. When used in combination with tobramycin, however, BSA essentially eradicated viable cells from both the planktonic and biofilm states. Likewise, A1-DM-His combined with tobramycin again eradicated the biofilm cells (consistent with the results shown in Fig. 2A) and left few viable cells in the planktonic state. In aggregate, these results indicated that the observed tobramycin synergy was not a function of any specific alginate lyase property but was more likely a nonspecific phenomenon stemming from biofilm exposure to proteins in general.

Amino acid treatment of mucoic biofilms. In an effort to assess whether intact primary/secondary/tertiary protein structure was required for antibiofilm synergy with tobramycin, a panel of

individual amino acid mixtures was examined next. Each treatment was based on the molar concentration of the individual constituent amino acids in 1,000 $\mu\text{g/ml}$ intact A1-III-His. Treatment with either the full complement of constituent amino acids (A1-III-His AA) or just the constituent arginines of A1-III-His (A1-III-His Arg) did not affect the biofilm cell signal but did increase the planktonic cell signal (Fig. 3B). Treatment with arginine at a molar concentration equal to that of the sum total of all individual constituent amino acids (arginine) yielded a 2-fold increase in the biofilm signal and a 5-fold increase in the planktonic cell signal. These observations suggest that the amino acids were used as a nutrient source in the otherwise nutrient-depleted buffer, and they are also consistent with the prior use of arginine as a growth supplement for *P. aeruginosa* biofilms (33). As observed in the earlier trials, tobramycin alone yielded only a moderate reduction in cell viability (36% for biofilm and 26% for planktonic cells). In combination with tobramycin, however, each of the amino acid treatments resulted in complete knockdown of the biofilm cell signal. The combined treatments were found to retain some level of planktonic cell viability, but the levels were at least 55% lower than those observed with tobramycin treatment alone. Thus, amino acid mixtures were as good as or even better than intact proteins with respect to bactericidal synergy toward biofilm cells.

Alginate lyase proteolytic sensitivity as a parameter in mucoic biofilm treatments. The above-mentioned results suggested that the alginate lyase treatments manifested antibiotic synergy by virtue of their consumption as a nutrient source, which would necessitate proteolytic degradation of the enzymes. As a preliminary test of this hypothesis, mucoic biofilms were treated with an active alginate lyase that had been conjugated to a 20-kDa poly-




FIG 4 Representative SEM images of FRD1 biofilms treated with buffer only (A), A1-III-His (B), A1-DM-His (C), A53C-His-PEG (D), A1-III-His AA (E), or BSA (F). The distinct architecture of biofilm matrix versus simple adherent cells is clear in panel A compared to panel B, C, D, or F.

ethylene glycol chain, i.e., PEGylated. PEGylation is a well-validated method of reducing the proteolytic susceptibility of proteins (34, 35), and the PEGylated alginate lyase (A53C-His-PEG) had been shown previously to exhibit wild-type solution phase kinetics and better than wild-type biofilm disruption (12). Treatment of mucoid biofilms with A1-III-His once again showed a decreased biofilm cell signal and at the same time an increased planktonic cell signal, which is consistent with enzyme-mediated detachment of biofilm cells (Fig. 3C). Similar to earlier results, A1-III-His combined with tobramycin essentially eradicated biofilm cells. Interestingly, treatment with AlgL-His alone caused an increase in both the biofilm cell signal and the planktonic cell signal. A combination of AlgL-His and tobramycin, however, yielded the expected knockdown of bacterial viability. Similar to AlgL alone, treatment with only A53C-His-PEG resulted in both increased biofilm cell signal and planktonic cell signal. In sharp contrast to all other combination treatments, however, A53C-His-PEG with tobramycin was no different than tobramycin alone. Thus, the PEGylated alginate lyase was the only biological treatment that failed to exhibit synergy with tobramycin.

Analysis of treatments by SEM. The alamarBlue assays of cell viability consistently pointed to a catalysis-independent mode of action for the alginate lyases, but to corroborate these results, the biofilm treatment studies were repeated and SEM was used to visualize treated biofilms in a direct fashion. Importantly, pre-SEM alamarBlue testing of these biofilms gave results matching those from the initial studies described above (data not shown). Representative images at $\times 8,000$ magnification (Fig. 4) highlight the differential effects of various treatments with respect to biofilm architecture, total biomass, and vitality of adherent cells. Blank buffer treatment of biofilms resulted in bacterial cells embedded within robust and copious extracellular matrix. In the absence of tobramycin, treatment with A1-III-His or A1-DM-His caused the nearly complete removal of extracellular matrix. As single agents, A53C-His-PEG and BSA also appeared to remove the majority of biofilm matrix, but each appeared to subtly increase the number of attached cells compared to biofilms treated

with the wild-type A1-III-His enzyme. Importantly, the qualitative SEM analysis of matrix removal by A1-III-His and A53C-His-PEG showed good agreement with prior quantitative analysis based on binding of an alginate-sensitive lectin (12). In contrast to the intact proteins, treatment with the constituent amino acids resulted in only partial removal of the biofilm matrix and a dramatic increase in the density of attached cells. Following treatment with biological agents, the bacteria generally appeared to have intact structure and regular shape, although some deviations from normal morphology were seen with the A53-His-PEG standalone treatment (Fig. 4D).

SEM analysis of biofilms treated with combinations of tobramycin and biologics again showed that the biological agents contributed to a reduction in extracellular matrix. Compared to the results from biological agents alone, the only differences were that the amino acid treatment with tobramycin left no identifiable matrix (compare Fig. 4E and 5E) while A53C-His-PEG with tobramycin yielded more matrix than the enzyme alone (compare Fig. 4D and 5D). More striking was the effect of tobramycin treatments on cellular integrity. As a single agent, the antibiotic yielded a subpopulation of adherent cells with atypical membrane morphology (Fig. 5A). The combination of tobramycin with A53C-His-PEG yielded largely similar results (Fig. 5D). In contrast, few if any intact adherent cells could be identified from biofilms treated with combinations of tobramycin and A1-III-His, A1-DM-His, BSA, or A1-III-His AA; only ghost cells were observed (Fig. 5B, C, E, and F).

Overall, SEM imaging correlated well with the results of alamarBlue viability analysis. One apparent discrepancy was the A53C-His-PEG treatment versus the PBS control. The quantitative alamarBlue studies showed that biofilms treated with the PEGylated enzyme exhibited almost 2-fold-higher signals than those treated with PBS. The SEM images, on the other hand, suggest a dramatic reduction in total biomass upon treatment with A53C-His-PEG. It is important to note that the alamarBlue reagent measures cellular metabolic activity, and it is therefore insensitive to biofilm matrix components, which constitute a sub-




FIG 5 SEM images of FRD1 biofilms treated with tobramycin (A), tobramycin and A1-III-His (B), tobramycin and A1-DM-His (C), tobramycin and A53C-His-PEG (D), tobramycin and A1-III-His AA (E), or tobramycin and BSA (F).

stantial fraction of the biomass seen in PBS-treated biofilms (Fig. 4A). Moreover, as noted above, some fraction of cells from A53C-His-PEG-treated biofilms exhibited anomalous morphology (Fig. 4D). This atypical morphology might correlate with altered cellular metabolic activity, which could in turn impact the alamarBlue assay. Together, these observations might explain the apparent discrepancy between alamarBlue and SEM analyses of A53C-His-PEG- versus PBS-treated biofilms.

DISCUSSION

P. aeruginosa's persistence in the CF airway can, to a large extent, be attributed to the bacterium's biofilm mode of growth (36). Additionally, *P. aeruginosa*'s transition to a mucoid phenotype in the majority of CF patients (1) leads to alginate-rich biofilms and enhanced antibiotic resistance (7). Therefore, disruption of the mucoid biofilm architecture with alginate lyases has long been considered a promising approach for enhancing antibiotic efficacy (16), and recent studies support this hypothesis (17, 19). In contrast, at least one report showed that exogenously added *Azobacter vinelandii* alginate lyase failed to remove mucoid *P. aeruginosa* biofilms despite the enzyme's confirmed activity toward the alginate substrate (37). One explanation for such an outcome is that the alginate biopolymer has a negligible contribution to mucoid biofilm adhesion (38). Regardless, the apparent disconnect between reports of alginate lyase antibiotic synergy versus enzyme-mediated biofilm disruption motivated the design of systematic studies to more fully assess the antibacterial potential of these biocatalysts.

Alginate lyase A1-III-His was selected over AlgL-His for the initial biofilm cell viability assays as a result of the enzyme's superior alginate degradation kinetics. SEM analysis showed that A1-III-His drastically reduced extracellular matrix compared to untreated and tobramycin-treated biofilms. Additionally, cotreatment of biofilms with A1-III-His and tobramycin demonstrated a vast improvement in cell killing compared to no treatment or tobramycin-only treatment. These results are consis-

tent with a long series of prior reports demonstrating cooperativity between alginate lyases and antibiotics (14, 16–18). Surprisingly, equivalent results were obtained in controlled studies with an isogenic nonmucoid strain that does not produce alginate exopolysaccharide. Although not peer reviewed, a recent report from the University of British Columbia found similar results with the nonmucoid *P. aeruginosa* strain PAO1 (39), which also fails to produce alginate under typical growth conditions (40). These observations suggested that alginate lyase catalytic activity was not a requisite factor for biofilm disruption or synergy with the antibiotic tobramycin. To test this hypothesis, we repeated our biofilm cell viability assays with the genetically inactivated alginate lyase A1-DM-His, as well as BSA sham treatments. Both catalytically inactive proteins yielded SEM evidence of biofilm dispersion and exhibited enhanced killing of biofilm cells when used in combination with tobramycin. Thus, biofilm dispersal and increased antibiotic efficacy appear to be nonspecific effects manifested by proteins in general. While early reports showed that heat-treated alginate lyase improved macrophage uptake of *P. aeruginosa* (15), the results reported here represent the first direct evidence that alginate lyase catalytic activity is superfluous to biofilm disruption and antibiotic synergy.

An alternative explanation for the antibiofilm effects of alginate lyases could be related to enzyme-mediated changes in cell physiology. Indeed, there is evidence that the growth behavior of *P. aeruginosa* and other biofilm-associated cells is a greater contributor to antibiotic resistance than any physical barrier the biofilm matrix might provide (41, 42). Nutrient limitation within biofilm communities leads to a general reduction in cellular metabolism (43), as well as specific response mechanisms that increase antibiotic tolerance (44). Another key piece of the puzzle is that *P. aeruginosa* biofilms can be dispersed by sudden increases in carbon source availability (45), and it has been shown that this effect depends upon protein synthesis (46). Additionally, arginine treatment is thought to upregulate the metabolism of *P. aeruginosa* in anaerobic biofilms, and it thereby increases antibiotic ef-

ficacy by 10- to 100-fold (47). Thus, even simple nutrients have the potential to profoundly influence adherent cell behavior and/or modulate antibiotic efficacy toward biofilms.

These insights motivated a hypothesis that, as opposed to actively degrading biofilm matrix, alginate lyases were acting as a nutrient source, modulating cellular metabolism and thus inducing cellular detachment and enhancing tobramycin efficacy. To test this hypothesis, biofilms were treated with the individual amino acid components of A1-III-His alginate lyase. With respect to enhancing tobramycin efficacy, the amino acid cotreatments matched the effectiveness of the intact enzyme. In the absence of tobramycin, however, SEM imaging showed the amino acid treatments failed to completely remove biofilm matrix surrounding the adherent cells. This contrasted with the intact A1-III-His, A1-DM-His, or BSA treatment, each of which individually resulted in complete erosion of the biofilm matrix. A potential explanation for the observed differences in the dispersive potential of intact proteins versus constituent amino acids relates to bioavailability. During infection, bacteria encounter nutrient-depleted environments and secrete proteases that can, through various mechanisms, facilitate degradation of host proteins for use as a nutrient source (48, 49). At the same time, several secreted pseudomonal proteases have been implicated in the degradation of structural proteins or adhesins that contribute to biofilm formation (50, 51). Together, these facts suggest a nonintuitive mechanism for the antibiofilm effects of alginate lyases: (i) biofilm bacteria sense the intact protein treatments and in response secrete proteases, (ii) subsequent assimilation of the freed amino acids upregulates cellular metabolism and renders the bacteria more susceptible to killing by tobramycin, and (iii) the secreted proteases destabilize key components of the biofilm matrix and initiate biofilm dissolution. Although this mechanism is speculative in nature, the literature supports each postulate independently, and their proposed connectivity is consistent with the observations reported here.

The above hypothesis was tested in a preliminary fashion by treating mucoid biofilms with the A53C-His-PEG alginate lyase, whose pendent 20-kDa PEG chain should at least partly shield the protein from proteases. Consistent with prior reports of the enzyme's ability to disrupt mucoid biofilms (12), SEM imaging revealed that A53C-His-PEG itself caused nearly complete dissolution of the biofilm matrix. The above-described mechanism would predict this outcome, if indeed the bacteria sensed the enzyme and subsequently secreted proteases. In contrast to all other intact protein treatments, however, a combination of A53C-His-PEG with tobramycin was no more effective at killing than treatment with tobramycin alone. Again, this is consistent with the proposed mechanism, if tobramycin synergy is ultimately dependent on the presence of individual amino acids, which are less readily liberated from the PEGylated enzyme. As a corollary, direct treatment of biofilms with constituent amino acids manifests a less pronounced degradation of biofilm matrix but fully replicates the intact proteins' synergy with tobramycin. Regardless of the mechanistic details, the studies reported here demonstrate that protein treatments nonspecifically promote *P. aeruginosa* biofilm dispersal, and they may enhance tobramycin efficacy through the action of their constituent amino acids.

Taken together, the above results reveal that complete biofilm dispersal is neither sufficient nor required for tobramycin synergy with biological cotreatments. Importantly, the results disclosed

here do not contradict prior reports of therapeutically relevant activity among alginate lyases. Indeed, they reinforce the widely published conclusions that this class of enzymes manifests biofilm-dispersive properties and synergy with antibiotics, yet the current studies are the first to probe the mechanism underlying these effects. In the biofilm model used here, alginate lyase catalytic activity is irrelevant to biofilm dispersion and tobramycin synergy. In fact, equivalent disruption of the biofilm matrix is achieved with the commodity protein BSA, and equivalent tobramycin synergy is achieved with either BSA or simple amino acids. While further work is required to extend the current studies to more clinically relevant models, it is clear that the long history of alginate lyase enzyme therapies should be reexamined with a more critical eye. In particular, the motivating assumption that enzymatic degradation of alginate would drive therapeutic effects may well be unfounded.

ACKNOWLEDGMENTS

This work was supported by grants from the National Center for Research Resources (5P20RR018787-10) and the National Institute of General Medical Sciences (8 P20 GM103413-10) of the National Institutes of Health. John W. Lamppa was also supported in part by a Renal Function and Disease Training Grant (T32 DK007301) from the NIH.

We thank Charles Daghighian and Louisa Howard for their assistance with the SEM imaging, as well as George O'Toole for the kind gift of strain SMC406 and critical comments on the manuscript.

REFERENCES

- Elkin S, Geddes D. 2003. Pseudomonal infection in cystic fibrosis: the battle continues. *Expert Rev. Anti Infect. Ther.* 1:609–618.
- Hoiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. 2001. *Pseudomonas aeruginosa* and the in vitro and in vivo biofilm mode of growth. *Microbes Infect.* 3:23–35.
- Smedley YM, Marriott Hodges CN, James SL. 1986. Rheological interactions of cystic fibrosis tracheal mucin and *Pseudomonas aeruginosa* extracellular alginate. *J. Pharm. Pharmacol.* 38:54P.
- Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. *Nature* 407:762–764.
- Davies JC, Bilton D. 2009. Bugs, biofilms, and resistance in cystic fibrosis. *Respir. Care* 54:628–638.
- Ramsey DM, Wozniak DJ. 2005. Understanding the control of *Pseudomonas aeruginosa* alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. *Mol. Microbiol.* 56:309–322.
- Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR. 2001. Alginate overproduction affects *Pseudomonas aeruginosa* biofilm structure and function. *J. Bacteriol.* 183:5395–5401.
- May TB, Shinabarger D, Maharaj R, Kato J, Chu L, DeVault JD, Roychoudhury S, Zielinski NA, Berry A, Rothmel RK. 1991. Alginate synthesis by *Pseudomonas aeruginosa*: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. *Clin. Microbiol. Rev.* 4:191–206.
- Murata K, Inose T, Hisano T, Abe S, Yonemoto Y, Yamashita T, Takagi M, Sakaguchi K, Kimura A, Imanaka T. 1993. Bacterial alginate lyase: enzymology, genetics and application. *J. Ferment. Bioeng.* 76:427–437.
- Mrsny RJ, Lazazzera BA, Daugherty AL, Schiller NL, Patapoff TW. 1994. Addition of a bacterial alginate lyase to purulent CF sputum in vitro can. Result in the disruption of alginate and modification of sputum viscoelasticity. *Pulm. Pharmacol.* 7:357–366.
- Strathmann M, Wingender J, Flemming H-C. 2002. Application of fluorescently labelled lectins for the visualization and biochemical characterization of polysaccharides in biofilms of *Pseudomonas aeruginosa*. *J. Microbiol. Methods* 50:237–248.
- Lamppa JW, Ackerman ME, Lai JJ, Scanlon TC, Griswold KE. 2011. Genetically engineered alginate lyase-PEG conjugates exhibit enhanced catalytic function and reduced immunoreactivity. *PLoS One* 6:e17042. doi:10.1371/journal.pone.0017042.
- Mai GT, Seow WK, Pier GB, McCormack JG, Thong YH. 1993. Sup-

- pression of lymphocyte and neutrophil functions by *Pseudomonas aeruginosa* mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments. *Infect. Immun.* 61:559–564.
14. Bayer AS, Speert DP, Park S, Tu J, Witt M, Nast CC, Norman DC. 1991. Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of *Pseudomonas aeruginosa*. *Infect. Immun.* 59:302–308.
 15. Eftekhar F, Speert DP. 1988. Alginase treatment of mucoid *Pseudomonas aeruginosa* enhances phagocytosis by human monocyte-derived macrophages. *Infect. Immun.* 56:2788–2793.
 16. Bayer AS, Park S, Ramos MC, Nast CC, Eftekhar F, Schiller NL. 1992. Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid *Pseudomonas aeruginosa*. *Infect. Immun.* 10:3979–3985.
 17. Alkawash MA, Soothill JS, Schiller NL. 2006. Alginate lyase enhances antibiotic killing of mucoid *Pseudomonas aeruginosa* in biofilms. *APMIS* 114:131–138.
 18. Hatch RA, Schiller NL. 1998. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 42:974–977.
 19. Alipour M, Sountres ZE, Omri A. 2009. Importance of DNase and alginase lyase for enhancing free and liposome encapsulated aminoglycoside activity against *Pseudomonas aeruginosa*. *J. Antimicrob. Chemother.* 64:317–325.
 20. Hisano T, Nishimura M, Yonemoto Y, Abe S, Yamashita T, Sakaguchi K, Kimura A, Murata K. 1993. Bacterial alginate lyase highly active on acetylated alginates. *J. Ferment. Bioeng.* 75:332–335.
 21. Sakakibara H, Tamura T, Suzuki TH, Abe TS, Murata K. 2002. Preparation and properties of alginate lyase modified with poly(ethylene glycol). *J. Pharm. Sci.* 91:1191–1199.
 22. Albrecht MT, Schiller NL. 2005. Alginate lyase (AlgL) activity is required for alginate biosynthesis in *Pseudomonas aeruginosa*. *J. Bacteriol.* 187:3869–3872.
 23. Jain S, Ohman DE. 2005. Role of an alginate lyase for alginate transport in mucoid *Pseudomonas aeruginosa*. *Infect. Immun.* 73:6429–6436.
 24. Hershberger CD, Ye RW, Parsek MR, Xie ZD, Chakrabarty AM. 1995. The algT (algU) gene of *Pseudomonas aeruginosa*, a key regulator involved in alginate biosynthesis, encodes an alternative sigma factor (sigma E). *Proc. Natl. Acad. Sci. U. S. A.* 92:7941–7945.
 25. Yoon H-J, Hashimoto W, Miyake O, Murata K, Mikami B. 2001. Crystal structure of alginate lyase A1-III complexed with trisaccharide product at 2.0 Å resolution. *J. Mol. Biol.* 307:9–16.
 26. Wingender J, Strathmann M, Rode A, Leis A, Flemming HC. 2001. Isolation and biochemical characterization of extracellular polymeric substances from *Pseudomonas aeruginosa*, p 302–314. In Doyle RJ (ed), *Microbial growth in biofilms*, part A. Academic Press Inc., San Diego, CA.
 27. Boyd A, Chakrabarty AM. 1994. Role of alginate lyase in cell detachment of *Pseudomonas aeruginosa*. *Appl. Environ. Microbiol.* 60:2355–2359.
 28. Schiller NL, Monday SR, Boyd CM, Keen NT, Ohman DE. 1993. Characterization of the *Pseudomonas aeruginosa* alginate lyase gene (algL): cloning, sequencing, and expression in *Escherichia coli*. *J. Bacteriol.* 175:4780–4789.
 29. Yamasaki M, Moriwaki S, Miyake O, Hashimoto W, Murata K, Mikami B. 2004. Structure and function of a hypothetical *Pseudomonas aeruginosa* protein PA1167 classified into family PL-7. *J. Biol. Chem.* 279:31863–31872.
 30. Pedersen SS, Espersen F, Hoiby N, Shand GH. 1989. Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid *Pseudomonas aeruginosa* from patients with cystic fibrosis. *J. Clin. Microbiol.* 27:691–699.
 31. Elkhatib WF, Noreddin AM. 2009. A new fluorogenic assay for monitoring and determining planktonic and biofilm forms of *Pseudomonas aeruginosa* viable count in vitro. *J. Rapid Methods Autom. Microbiol.* 17:304–314.
 32. Novartis Pharmaceuticals. 2010. Prescribing information for ^PrTobi* (tobramycin solution for inhalation) 300 mg/5 ml tobramycin (as sulfate) respiratory antibiotic. Novartis Pharmaceuticals, Dorval, Quebec, Canada.
 33. Caiazza NC, O'Toole GA. 2004. SadB is required for the transition from reversible to irreversible attachment during biofilm formation by *Pseudomonas aeruginosa* PA14. *J. Bacteriol.* 186:4476–4485.
 34. Kadera Y, Matsushima A, Hiroto M, Nishimura H, Ishii A, Ueno T, Inada Y. 1998. Pegylation of proteins and bioactive substances for medical and technical applications. *Progr. Polymer Sci.* 23:1233–1271.
 35. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. *Nat. Rev. Drug Discov.* 2:214–221.
 36. Høiby N, Ciofu O, Bjarnsholt T. 2010. *Pseudomonas aeruginosa* biofilms in cystic fibrosis. *Future Microbiol.* 5:1663–1674.
 37. Christensen BE, Ertesvag H, Beyenal H, Lewandowski Z. 2001. Resistance of biofilms containing alginate-producing bacteria to disintegration by an alginate degrading enzyme (AlgL). *Biofouling* 17:203–210.
 38. Xavier JB, Picioreanu C, Rani SA, van Loosdrecht MCM, Stewart PS. 2005. Biofilm-control strategies based on enzymic disruption of the extracellular polymeric substance matrix: a modelling study. *Microbiology* 151:3817–3832.
 39. Cotton LA, Graham RJ, Lee RJ. 2009. The role of alginate in *P. aeruginosa* PAO1 biofilm structural resistance to gentamicin and ciprofloxacin. *J. Exp. Microbiol. Immunol.* 13:58–62.
 40. Wozniak DJ, Wyckoff TJO, Starkey M, Keyser R, Azadi P, O'Toole GA, Parsek MR. 2003. Alginate is not a significant component of the extracellular polysaccharide matrix of PA14 and PAO1 *Pseudomonas aeruginosa* biofilms. *Proc. Natl. Acad. Sci. U. S. A.* 100:7907–7912.
 41. Walters MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. 2003. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of *Pseudomonas aeruginosa* biofilms to ciprofloxacin and tobramycin. *Antimicrob. Agents Chemother.* 47:317–323.
 42. Qu Y, Daley AJ, Istivan TS, Rouch DA, Deighton MA. 2010. Densely adherent growth mode, rather than extracellular polymer substance matrix build-up ability, contributes to high resistance of *Staphylococcus epidermidis* biofilms to antibiotics; authors' response. *J. Antimicrob. Chemother.* 65:2055–2056.
 43. Stewart PS, Franklin MJ. 2008. Physiological heterogeneity in biofilms. *Nat. Rev. Microbiol.* 6:199–210.
 44. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay G, Siehn R, Schafhauser J, Wang Y, Britigan BE, Singh PK. 2011. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. *Science* 334:982–986.
 45. Sauer K, Cullen MC, Rickard AH, Zeef LAH, Davies DG, Gilbert P. 2004. Characterization of nutrient-induced dispersion in *Pseudomonas aeruginosa* PAO1 biofilm. *J. Bacteriol.* 186:7312–7326.
 46. Roy AB, Petrova OE, Sauer K. 2012. The phosphodiesterase DipA (PA5017) is essential for *Pseudomonas aeruginosa* biofilm dispersion. *J. Bacteriol.* 194:2904–2915.
 47. Borriello G, Richards L, Ehrlich GD, Stewart PS. 2006. Arginine or nitrate enhances antibiotic susceptibility of *Pseudomonas aeruginosa* in biofilms. *Antimicrob. Agents Chemother.* 50:382–384.
 48. Travis J, Potempa J. 2000. Bacterial proteinases as targets for the development of second-generation antibiotics. *Biochim. Biophys. Acta* 1477:35–50.
 49. Supuran CT, Scozzafava A, Clare BW. 2002. Bacterial protease inhibitors. *Med. Res. Rev.* 22:329–372.
 50. Nikolaev YA, Panikov NS. 2002. Extracellular protease as a reversible adhesion regulator in *Pseudomonas fluorescens*. *Microbiology* 151:541–545.
 51. Tienen P, Rosenau F, Wilhelm S, Jaeger K-E, Flemming Wingender H-CJ. 2010. Extracellular enzymes affect biofilm formation of mucoid *Pseudomonas aeruginosa*. *Microbiology* 156:2239–2252.